Medical Markup Language (MML) is a standard for the exchange of medical data among different medical institutions. It was developed in Japan in 1995. Since version 2.21, MML has used eXtensible Markup Language (XML) as a meta-language. The latest version, 3.0, conforms to HL7 Clinical Document Architecture (CDA) and contains 14 modules and 36 data definition tables. In China, a standard which structures entire medical records in XML does not yet exist. Taking advantage of MML's flexibility, we created a localized Chinese version based on MML 3.0. Parts of the original specifications have been enhanced; these include a newly developed health insurance information module and 12 additional or redefined data definition tables. The Chinese version takes local needs into account and now makes it possible to exchange medical data among Chinese medical institutions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10916-005-6111-7 | DOI Listing |
J Am Med Inform Assoc
January 2025
Kennewick, WA 99338, United States.
Objective: This study evaluates the utility of word embeddings, generated by large language models (LLMs), for medical diagnosis by comparing the semantic proximity of symptoms to their eponymic disease embedding ("eponymic condition") and the mean of all symptom embeddings associated with a disease ("ensemble mean").
Materials And Methods: Symptom data for 5 diagnostically challenging pediatric diseases-CHARGE syndrome, Cowden disease, POEMS syndrome, Rheumatic fever, and Tuberous sclerosis-were collected from PubMed. Using the Ada-002 embedding model, disease names and symptoms were translated into vector representations in a high-dimensional space.
Rheumatology (Oxford)
January 2025
Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Objectives: To clarify the differences in clinical phenotypes, therapeutic patterns, and outcomes of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) across geographic regions using a multinational cohort.
Methods: Data were collected from patients with newly diagnosed or relapsing GPA or MPA in Europe, Japan, and the United States (US) from January to July 2020. The composite outcome of kidney failure and/or death within 52 weeks after treatment was evaluated, and the hazard ratios across the regions were estimated using the Cox proportional hazard model.
Rehabil Psychol
January 2025
Department of Psychology, Brandenburg Medical School Theodor Fontane.
Purpose/objective: This study investigated the development of posttraumatic growth (PTG) in relatively young persons with stroke. It examined the contribution of potential predictive variables and their changes over time.
Research Method/design: Participants completed questionnaires at baseline ( = 78, median time since injury = 47 days) and 3 ( = 53) and 6 months ( = 47) later.
Allergol Immunopathol (Madr)
January 2025
Department of Pediatrics, University Hospital of Ioannina, Ioannina, Greece.
Anaphylaxis, the most severe end of the spectrum of allergic reactions, has shown increasing incidence globally over recent years. This hypersensitivity reaction can occur at any age, including infancy. Recent data, although scarce, show that anaphylaxis is increasingly reported in infancy, with food identified as the leading cause of anaphylaxis cases in this age group.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Department of Epidemiology and Public Health, Ehime University Graduate School of Medicine, Ehime, Japan.
Background: There is limited evidence on the association between maternal anemia during pregnancy and the risk of childhood allergic disorders, with regards to atopic eczema. The current pre-birth cohort study aimed to examine the association between maternal anemia during pregnancy and the risk of atopic eczema in Japanese 2-year-olds.
Methods: The study included 1354 Japanese mother-child pairs.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!